Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

Larry M. Karnitz, Karen S. Flatten, Jill M. Wagner, David Loegering, Jennifer S. Hackbarth, Sonnet J. H. Arlander, Benjamin T. Vroman, M. Bijoy Thomas, Yong-Un Baek, Kevin M. Hopkins, Howard B. Lieberman, Junjie Chen, William A. Cliby and Scott H. Kaufmann
Molecular Pharmacology December 2005, 68 (6) 1636-1644; DOI: https://doi.org/10.1124/mol.105.012716
Larry M. Karnitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen S. Flatten
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill M. Wagner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Loegering
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer S. Hackbarth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonnet J. H. Arlander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin T. Vroman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Bijoy Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong-Un Baek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin M. Hopkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard B. Lieberman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junjie Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Cliby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott H. Kaufmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Two signaling pathways are activated by antineoplastic therapies that damage DNA and stall replication. In one pathway, double-strand breaks activate ataxia-telangiectasia mutated kinase (ATM) and checkpoint kinase 2 (Chk2), two protein kinases that regulate apoptosis, cell-cycle arrest, and DNA repair. In the second pathway, other types of DNA lesions and replication stress activate the Rad9-Hus1-Rad1 complex and the protein kinases ataxia-telangiectasia mutated and Rad3-related kinase (ATR) and checkpoint kinase 1 (Chk1), leading to changes that block cell-cycle progression, stabilize stalled replication forks, and influence DNA repair. Gemcitabine and cytarabine are two highly active chemotherapeutic agents that disrupt DNA replication. Here, we examine the roles these pathways play in tumor cell survival after treatment with these agents. Cells lacking Rad9, Chk1, or ATR were more sensitive to gemcitabine and cytarabine, consistent with the fact that these agents stall replication forks, and this sensitization was independent of p53 status. Interestingly, ATM depletion sensitized cells to gemcitabine and ionizing radiation but not cytarabine. Together, these results demonstrate that 1) gemcitabine triggers both checkpoint signaling pathways, 2) both pathways contribute to cell survival after gemcitabine-induced replication stress, and 3) although gemcitabine and cytarabine both stall replication forks, ATM plays differential roles in cell survival after treatment with these agents.

  • Received March 10, 2005.
  • Accepted August 26, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 68 (6)
Molecular Pharmacology
Vol. 68, Issue 6
1 Dec 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

Larry M. Karnitz, Karen S. Flatten, Jill M. Wagner, David Loegering, Jennifer S. Hackbarth, Sonnet J. H. Arlander, Benjamin T. Vroman, M. Bijoy Thomas, Yong-Un Baek, Kevin M. Hopkins, Howard B. Lieberman, Junjie Chen, William A. Cliby and Scott H. Kaufmann
Molecular Pharmacology December 1, 2005, 68 (6) 1636-1644; DOI: https://doi.org/10.1124/mol.105.012716

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

Larry M. Karnitz, Karen S. Flatten, Jill M. Wagner, David Loegering, Jennifer S. Hackbarth, Sonnet J. H. Arlander, Benjamin T. Vroman, M. Bijoy Thomas, Yong-Un Baek, Kevin M. Hopkins, Howard B. Lieberman, Junjie Chen, William A. Cliby and Scott H. Kaufmann
Molecular Pharmacology December 1, 2005, 68 (6) 1636-1644; DOI: https://doi.org/10.1124/mol.105.012716
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics